Raleigh, NC, United States of America

Daniel Logan Kirschner

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 2020-2023

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Daniel Logan Kirschner

Introduction

Daniel Logan Kirschner is an accomplished inventor based in Raleigh, NC, with a notable portfolio of four patents. His work primarily focuses on pharmaceutical compositions that address critical health issues, particularly in pediatric patients.

Latest Patents

One of Kirschner's latest patents involves anhydrous sodium thiosulfate and its formulations. This invention describes methods for synthesizing anhydrous sodium thiosulfate, which is created from sodium sulfite, sulfur, and cetylpyridinium chloride. The resulting pharmaceutical compositions are designed to eliminate or reduce ototoxicity in pediatric patients undergoing treatment with platinum-based chemotherapeutics. This innovative approach has the potential to significantly improve the quality of life for young patients facing the side effects of their treatments.

Career Highlights

Kirschner is currently associated with Fennec Pharmaceuticals, Inc., where he continues to contribute to advancements in pharmaceutical science. His expertise in synthesizing complex compounds has positioned him as a valuable asset in the field.

Collaborations

Throughout his career, Kirschner has collaborated with notable colleagues, including Thomas Claiborne Lovelace and Joseph Alexander Moore, III. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Daniel Logan Kirschner's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving patient care. His work in developing formulations to combat ototoxicity showcases the impact of his inventions on the medical community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…